PDCD1 and neoplasm: The development of immune checkpoint inhibitor (ICI) immunotherapies including anti-programmed cell death-1 (PD-1)/PD-L1 and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) have significantly improved survival and clinical outcomes in a subset of patients with certain tumor types [1–3].